Interview with Robin Rumler, CEO, Pfizer Austria
Dr. Rumler, what is your assessment of the subsidiary’s current strengths and weaknesses, after three and half years of tenure? Pfizer currently ranks second in the overall pharmaceutical market in…
Address: AGES
Federal Office for the Safety in Health Care (BASG)
Traisengasse 5 | 1200 Vienna,Austria
Tel: +43 (0)664 831 28 43
The Federal Office for the Safetyin Health Care (BASG) / AGES was set up in January 2006 and is responsible for marketing authorisation of medicinal products in Austria and assessment of medicinal products and medical devices which are already on the market regarding efficacy, adverse reactions, production, shipment and storage.
Fully owned by the Republic of Austria, BASG / AGES acts on behalf of the Republic as represented by the Federal Ministry of Health (BMG).
The Federal Office for Safety in Health Care (BASG) is responsible for carrying out public services undertakings. BASG is directly subordinate to the Federal Ministry of Health (BMG). It consists of three members, which are appointed by the Federal Minister of Health. One of these members was delegated by the BMG, another by AGES; the third member is the head of BASG / AGES.
AGES is thus connected closely to the BASG; it is represented by two members in the Federal Office and provides it with services, staff and facilities. The employees of BASG / AGES are responsible for carrying out public services undertakings and act on behalf of the Federal Office. The written decisions issued by the BASG are not subject to reversal change by the administration, thus making it the first and final authority.
Dr. Rumler, what is your assessment of the subsidiary’s current strengths and weaknesses, after three and half years of tenure? Pfizer currently ranks second in the overall pharmaceutical market in…
Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the company established its first…
Dr Spatz, what would you highlight as the main specificities of the Austrian generic market, and explain how Teva has adapted its approach to the Austrian environment? Teva recently changed…
Just like other European countries, Austria is in the search for meaningful savings in healthcare. Austria’s increasingly price sensitive pharma market is seeing the rise of generic medicines gaining market…
Whereas most General Managers are exposed to different countries during their professional career, you have chosen to dedicate yours to the Austrian market. What is it in this country so…
You have been General Secretary of PHARMIG since 2004 and have witnessed the market’s development over the past 8 years. What have been the most important changes since you started…
See our Cookie Privacy Policy Here